Indian Journal of Drugs in Dermatology

: 2016  |  Volume : 2  |  Issue : 2  |  Page : 75--82

Apremilast: A dermatologic perspective

Aditya Kumar Bubna 
 Department of Dermatology, Sri Ramachandra University, Chennai, Tamil Nadu, India

Correspondence Address:
Aditya Kumar Bubna
Department of Dermatology, Sri Ramachandra University, Porur, Chennai - 600 116, Tamil Nadu

Apremilast is an oral phosphodiesterase 4 inhibitor, now approved by the Food and Drug Administration in the management of psoriatic arthropathy (PsA). As biologic therapy is associated with significant amounts of adverse effects, newer treatment options with an efficacious outcome, sans the toxicity, is something all clinicians would implement readily in their therapeutic regimens. Apremilast is one such drug which has shown promise in the management of psoriasis, PsA, and a few other dermatologic disorders. This review will throw light on the dermatologic perspective regarding apremilast.

How to cite this article:
Bubna AK. Apremilast: A dermatologic perspective.Indian J Drugs Dermatol 2016;2:75-82

How to cite this URL:
Bubna AK. Apremilast: A dermatologic perspective. Indian J Drugs Dermatol [serial online] 2016 [cited 2022 Nov 29 ];2:75-82
Available from:;year=2016;volume=2;issue=2;spage=75;epage=82;aulast=Bubna;type=0